Foghorn Therapeutics Inc   (FHTX)
Other Ticker:  
Price: $7.9400 $0.21 2.717%
Day's High: $8.44 Week Perf: 5.31 %
Day's Low: $ 7.74 30 Day Perf: 149.69 %
Volume (M): 133 52 Wk High: $ 9.97
Volume (M$): $ 1,053 52 Wk Avg: $6.05
Open: $7.76 52 Wk Low: $2.70

 Market Capitalization (Millions $) 334
 Shares Outstanding (Millions) 42
 Employees -
 Revenues (TTM) (Millions $) 33
 Net Income (TTM) (Millions $) -103
 Cash Flow (TTM) (Millions $) -31
 Capital Exp. (TTM) (Millions $) 3

Foghorn Therapeutics Inc
Foghorn Therapeutics Inc is a biotechnology company that focuses on developing precision medicines for patients with diseases caused by gene dysregulation. The company utilizes its proprietary Gene Traffic Control platform to gain insights into the role of chromatin regulation in gene expression and identify potential therapeutic targets. By targeting the complex mechanisms that control gene expression, Foghorn aims to develop innovative and transformative therapies for various diseases, including cancer and neurodegenerative disorders. The company is committed to advancing the understanding of gene regulation and translating their findings into novel treatments that have the potential to improve patient outcomes.

   Company Address: 500 Technology Square, Ste 700 Cambridge 2139 MA
   Company Phone Number: 586-3100   Stock Exchange / Ticker: NASDAQ FHTX
   FHTX is expected to report next financial results on March 08, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Foghorn Therapeutics' FHD-909: A Promising Breakthrough in Targeted Lung Cancer Therapy

Published Thu, Feb 8 2024 12:01 PM UTC

In an exciting development for the field of precision medicine, Foghorn Therapeutics Inc. has recently announced that its novel oral BRM selective inhibitor, FHD-909, has been selected by pharmaceutical giant Lilly for clinical development. This cutting-edge therapy holds immense potential in treating a specific subset of non-small cell lung cancer (NSCLC) patients with BRG1...

Clinical Study

Precision Medicine Unveiled: Navigating the Therapeutic Landscape for AML and EGFR/KRAS Resistance with Foghorn Therapeutics' FHD-286

Published Mon, Jan 8 2024 12:02 PM UTC

Unleashing the Power of Precision Medicine: Updates and Future Directions in Foghorn Therapeutics' Clinical ProgramPrecision medicine has revolutionized the field of oncology by providing targeted therapies that specifically address the genetic alterations driving cancer growth. Foghorn Therapeutics, a leading biotechnology company, is at the forefront of this exciting front...

Clinical Study

Foghorn Therapeutics Unveils Promising Clinical Data for FHD-286: A Novel Treatment for Advanced Hematologic Malignancies

Published Fri, Dec 1 2023 12:00 PM UTC

CAMBRIDGE, Mass., Dec. 01, 2023 - Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company dedicated to correcting abnormal gene expression in the treatment of serious diseases, has exciting news to share. The company announced today that clinical data from the Phase 1 dose escalation study of their groundbreaking drug, FHD-286, will be presented...

Foghorn Therapeutics Inc

Foghorn Therapeutics Inc Surges with a Remarkable Performance in the Exhilarating Financial Third Quarter of 2023

Foghorn Therapeutics Inc (Nasdaq: FHTX), a clinical-stage biotechnology company focusing on developing innovative therapies for diseases through gene expression correction, recently released its financial results for the most recent fiscal period. These results indicate a significant improvement in key financial metrics compared to the previous reporting periods.
Financial Performance:
For the most recent fiscal period, Foghorn Therapeutics Inc reported a decrease in loss per share, reaching $-0.34 per share, as compared to $-0.62 per share from the previous year. Furthermore, earnings per share (EPS) witnessed a remarkable improvement, advancing from $-0.70 per share in the prior reporting period. These figures demonstrate a strengthening of the company's financial health and potential profitability.

Foghorn Therapeutics Inc

Trailblazing Profit Leap for Foghorn Therapeutics Inc. in the 2023 Fiscal Second Quarter as Revenue Skyrockets

Foghorn Therapeutics Inc, a biotechnology company, has announced a substantial surge in revenue during the fiscal second quarter of 2023. The company reported a revenue increase of 24.699% to $5.60 million, compared to the same reporting period a year ago. Despite this positive revenue growth, the company experienced diminishing returns, with an extended deficit of $-0.70 per share.
Nevertheless, there is some positive news for Foghorn Therapeutics. In comparison to the previous reporting period, the company's earnings per share (EPS) improved from $-0.73 per share. Additionally, revenue saw a 5.462% increase, rising from $5.31 million. This indicates that the company is successfully combining its high growth rates with more favorable consumer prices and demonstrating organizational and operational excellence.


Foghorn Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com